306 / 1068
HPV & ANAL CANCER
•
143 stage I – III anal SCCs ( 2000 – 2010 )
•
Single centre in Denmark
•
52 % treated with RT ; 48 % treated with CRT
•
Median F.U 51.2 months
•
Recurrent disease in 23 %
•
87.6 % HPV +
( 79.6% HPV16 )
•
92.9 % p16 +
Overall Survival
Disease Specific Survival
HPV +
74 %
84 %
HPV -
52 %
52 %
p16 +
76 %
85 %
p16 -
30 %
30 %
( Serup-Hansen et al 2014 )